Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer
Hyundai Bioscience announced on April 25th that its clinical development plan of oral “Niclosamide Metabolic Anticancer Drug” targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost all cancer types and cause intractable…
EVERSANA Completes Integration of Healthware Group and Strengthens Its Global Agency Network EVERSANA INTOUCH With Addition of New Full-Service Affiliate
EVERSANA, a leading provider of global commercial services to the life sciences industry, today unveiled a new full-service affiliate in its EVERSANA INTOUCH global agency network, EVERSANA INTOUCH Healthware. Today’s announcement comes following the October 2023 acquisition of Healthware Group, an agency and innovation consultancy headquartered…
Unlocking the Future of Drug Discovery with Artificial Intelligence
BCC’s newly released report, titled “Global Artificial Intelligence in Drug Discovery Market,” unveils the extraordinary impact of artificial intelligence (AI) on the pharmaceutical and biotech sectors. Authored by Ms. Surbhi Jagtap, Senior Analyst, this study provides invaluable insights into the…
Vial to Sponsor the 4th Annual Gene Therapy for Ophthalmic Disorders Conference 2023 in Boston, MA
Vial, a global full-service CRO providing tech-forward clinical trial management services, announced its participation as a sponsor and speaker at the 4th Annual Gene Therapy for Ophthalmic Disorders Conference in Boston, MA, October 3-5, 2023, at the Hilton Boston Back…
